Furthermore, combining CD47 blockade (administered every day since diagnosis) with the anthracycline mitoxantrone (MTX) (administered once, upon the diagnosis of the tumor) showed that the attained reduction in tumor growth was even more significant than when these two types of treatment were used separately. This evidence concerns the gene CD47 and neoplasm.